6CM
HRMY icon

683 Capital Management’s Harmony Biosciences HRMY Stock Holding History

683 Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$535K Hold
14,700
– – 0.03% 130
2026
Q1 		$412K Buy
+14,700
New +$482K 0.02% 197

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

683 Capital Management's HRMY Position: Q2 2026 in Review

683 Capital Management opened a new position in Harmony Biosciences (HRMY) in Q2 2026: 294,000 shares worth $10.7M. The stake represents 0.53% of the portfolio and ranks #45 among its holdings. This is a return to the name: 683 Capital Management previously reported a position in HRMY as recently as Q4 2025.

683 Capital Management first reported a position in HRMY in Q1 2023 and has held it in 13 quarters since. The position peaked at $15.5M in Q4 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • 683 Capital Management held 294,000 shares of Harmony Biosciences worth $10.7M as of Q2 2026.
  • Harmony Biosciences was a new 683 Capital Management position in Q2 2026.
  • Harmony Biosciences made up 0.53% of 683 Capital Management's portfolio in Q2 2026, its #45 holding.
  • 683 Capital Management first reported a position in Harmony Biosciences in Q1 2023 and has held it in 13 quarters since.
  • 683 Capital Management's Harmony Biosciences position peaked at $15.5M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.